Plymouth Meeting, PA - Geneos Therapeutics, a leading biotechnology research company focused on developing personalized immunotherapies for cancer treatment, announced today the successful completion of its Series A funding round. The company has raised $5 million in funding from 3B Future Health Fund I & II, a venture capital and private equity principal.

Geneos Therapeutics, co-founded by Niranjan Sardesai, is headquartered in Plymouth Meeting, PA, and is committed to harnessing the power of the body's own immune system to fight cancer. Geneos' GT-EPIC platform is a breakthrough technology that identifies and targets neoantigens, which are unique proteins found on the surface of cancer cells. By leveraging these neoantigens, Geneos can develop personalized immunotherapies that specifically target and destroy cancer cells, while minimizing harm to healthy cells.

"We are thrilled to receive this funding from 3B Future Health Fund I & II, which will enable us to accelerate the development of our GT-EPIC platform and advance our personalized immunotherapies to clinical trials," said Niranjan Sardesai, co-founder of Geneos Therapeutics. "This funding will also help us expand our team and infrastructure to support the growing demand for personalized cancer immunotherapies."